Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial

LK Bolt; GP Amminger; J Farhall; PD McGorry; B Nelson; C Markulev; HP Yuen; MR Schäfer; N Mossaheb; M Schlögelhofer; S Smesny; IB Hickie; GE Berger; EYH Chen; L de Haan; DH Nieman; M Nordentoft; A Riecher-Rössler; S Verma; A Thompson; AR Yung; KA Allott

Journal article

Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial

LK Bolt, GP Amminger, J Farhall, PD McGorry, B Nelson, C Markulev, HP Yuen, MR Schäfer, N Mossaheb, M Schlögelhofer, S Smesny, IB Hickie, GE Berger, EYH Chen, L de Haan, DH Nieman, M Nordentoft, A Riecher-Rössler, S Verma, A Thompson Show all

Schizophrenia Research | ELSEVIER | Published : 2019

DOI: 10.1016/j.schres.2018.12.013

Abstract

Background: Neurocognitive impairments experienced by individuals at ultra-high risk (UHR) for psychosis are potential predictors of outcome within this population, however there is inconsistency regarding the specific neurocognitive domains implicated. This study aimed to examine whether baseline neurocognition predicted transition to psychosis, or functional outcomes, at medium-term (mean = 3.4 years) follow-up, while controlling for other clinical/treatment variables associated with transition to psychosis. Method: Analysis of data collected as part of a multi-centre RCT of omega-3 fatty acids and cognitive-behavioural case management (NEURAPRO) for UHR individuals was conducted on the 29..

View full abstract

University of Melbourne Researchers

Paul Amminger Author

Patrick McGorry Author

Barnaby Nelson Author

Connie Markulev Author

Related Projects (4)

EMERGING MENTAL DISORDERS IN YOUNG PEOPLE: USING CLINICAL STAGING FOR PREDICTION, PREVENTION AND EARLY INTERVENTION

Mental disorders are a major cause of disability in Australia, especially for young people. We have developed a clinical staging model cover..

LIPID BIOLOGY FOR PREDICTION AND PREVENTION OF PSYCHOTIC DISORDERS AND PERSISTENT DEPRESSION IN YOUNG PEOPLE

My vision for the next 5 years is to establish ω-3PUFAs as a first-line treatment for indicated prevention of psychosis and persistent depre..

MAPPING AND TREATING EARLY CLINICAL STAGES OF MENTAL DISORDERS DURING TRANSITION TO ADULTHOOD

The research proposed in this Fellowship is aimed at young people with emerging mental ill-health. The specific goals and targets are to for..

CLINICAL PREDICTORS OF OUTCOME IN THE ULTRA HIGH RISK FOR PSYCHOSIS ("PRODROMAL") POPULATION

This area of research is concerned with improving our ability to identify young help-seeking patients who are most at risk of developing psy..

Grants

Awarded by Stanley Medical Research Institute

Funding Acknowledgements

This work was supported by grant 07TGF-1102 from the StanleyMedical Research Institute, grant 566529 from the NHMRC Australia Program(Drs McGorry, Hickie, and Yung, and Amminger), and a grant from the Colonial Foundation. Dr. Allott was supported by a Ronald Philip Griffiths Fellowship from The University of Melbourne; Dr. McGorry was supported by Senior Principal Research Fellowship 1060996 from the National Health and Medical Research Council of Australia (NHMRC); Drs Yung and Amminger were supported by NHMRC Senior Research Fellowships 1080963 and 566593, respectively; and Dr. Nelson was supported by NHMRC Career Development Fellowship 1027532. These funding sources had no input into the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.